Objectives
The primary objective of this study was to evaluate whether patients
under antihypertensive treatment with β-blockers or ACEI show more
systemic AE during VIT compared with patients without antihypertensive
therapy.
Secondary objectives included the evaluation of whether patients under
antihypertensive treatment (β-blockers or ACEI) have more severe SSR and
whether prevalence of cardiovascular diseases or hypertension is
associated with the risk of more severe SSR and more frequent systemic
AE during VIT. Furthermore, we evaluated whether bee venom, high sIgE
levels, high tryptase levels, or quicker up-dosing protocols are
correlated with a higher frequency of systemic AE. In addition, the
effectiveness of VIT was monitored by the outcome of sting challenges or
field stings, and these results were compared between patients with and
without antihypertensive treatment.